Pulmonx (STU:4NI) Change In Payables And Accrued Expense : €-0.53 Mil (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Pulmonx Change In Payables And Accrued Expense?

Pulmonx's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2024 was €1.61 Mil. It means Pulmonx's Accounts Payable & Accrued Expense increased by €1.61 Mil from Mar. 2024 to Jun. 2024 .

Pulmonx's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €2.66 Mil. It means Pulmonx's Accounts Payable & Accrued Expense increased by €2.66 Mil from Dec. 2022 to Dec. 2023 .

Pulmonx Change In Payables And Accrued Expense Historical Data

The historical data trend for Pulmonx's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx Change In Payables And Accrued Expense Chart

Pulmonx Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

3.67

1.20

4.34

0.26

2.66

Pulmonx Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															2.25	1.24	0.65	-4.02	1.61

Pulmonx Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.53 Mil.

Pulmonx Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Pulmonx's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulmonx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (STU:4NI) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

LUNG:USA

Address

700 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.pulmonx.com

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.

Pulmonx Headlines

No Headlines